Beijing Strong Biotechnologies, Inc. (300406.SZ)
CNY 14.0
(0.65%)
CNY 14.0
(0.65%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.45 Billion CNY | 8.19% |
| 2022 | 1.34 Billion CNY | -4.43% |
| 2021 | 1.4 Billion CNY | 160.34% |
| 2020 | 540.19 Million CNY | 195.05% |
| 2019 | 183.08 Million CNY | 12.65% |
| 2018 | 162.52 Million CNY | -34.64% |
| 2017 | 248.64 Million CNY | 199.26% |
| 2016 | 83.08 Million CNY | -4.01% |
| 2015 | 86.56 Million CNY | 50.68% |
| 2014 | 57.44 Million CNY | 28.88% |
| 2013 | 44.57 Million CNY | -4.78% |
| 2012 | 46.81 Million CNY | 66.97% |
| 2011 | 28.03 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.43 Billion CNY | -1.26% |
| 2024 Q3 | 1.49 Billion CNY | 5.25% |
| 2024 Q2 | 1.41 Billion CNY | -1.23% |
| 2023 Q3 | 1.39 Billion CNY | 4.77% |
| 2023 Q4 | 1.45 Billion CNY | 4.29% |
| 2023 Q1 | 1.3 Billion CNY | -2.54% |
| 2023 Q2 | 1.33 Billion CNY | 1.61% |
| 2023 FY | 1.45 Billion CNY | 8.19% |
| 2022 Q4 | 1.34 Billion CNY | -5.73% |
| 2022 FY | 1.34 Billion CNY | -4.43% |
| 2022 Q2 | 1.31 Billion CNY | 1.64% |
| 2022 Q1 | 1.29 Billion CNY | -8.18% |
| 2022 Q3 | 1.42 Billion CNY | 8.63% |
| 2021 Q4 | 1.4 Billion CNY | 35.32% |
| 2021 Q1 | 487.04 Million CNY | -9.84% |
| 2021 Q2 | 555.77 Million CNY | 14.11% |
| 2021 FY | 1.4 Billion CNY | 160.34% |
| 2021 Q3 | 1.03 Billion CNY | 87.0% |
| 2020 Q4 | 540.19 Million CNY | 0.75% |
| 2020 Q3 | 536.18 Million CNY | 96.31% |
| 2020 Q2 | 273.12 Million CNY | 13.54% |
| 2020 Q1 | 240.55 Million CNY | 31.39% |
| 2020 FY | 540.19 Million CNY | 195.05% |
| 2019 Q2 | 89.05 Million CNY | 12.6% |
| 2019 Q4 | 183.08 Million CNY | 81.39% |
| 2019 Q1 | 79.08 Million CNY | -51.34% |
| 2019 FY | 183.08 Million CNY | 12.65% |
| 2019 Q3 | 100.93 Million CNY | 13.35% |
| 2018 Q3 | 181.81 Million CNY | 4.09% |
| 2018 FY | 162.52 Million CNY | -34.64% |
| 2018 Q4 | 162.52 Million CNY | -10.61% |
| 2018 Q2 | 174.68 Million CNY | 4.46% |
| 2018 Q1 | 167.22 Million CNY | -32.75% |
| 2017 Q3 | 95.78 Million CNY | -9.28% |
| 2017 Q4 | 248.64 Million CNY | 159.59% |
| 2017 FY | 248.64 Million CNY | 199.26% |
| 2017 Q1 | 91.12 Million CNY | 9.67% |
| 2017 Q2 | 105.57 Million CNY | 15.87% |
| 2016 Q2 | 83.72 Million CNY | 8.02% |
| 2016 Q4 | 83.08 Million CNY | 10.32% |
| 2016 FY | 83.08 Million CNY | -4.01% |
| 2016 Q1 | 77.51 Million CNY | -10.45% |
| 2016 Q3 | 75.31 Million CNY | -10.05% |
| 2015 Q2 | 79.4 Million CNY | 53.86% |
| 2015 Q4 | 86.56 Million CNY | 32.24% |
| 2015 Q3 | 65.45 Million CNY | -17.57% |
| 2015 Q1 | 51.6 Million CNY | -10.16% |
| 2015 FY | 86.56 Million CNY | 50.68% |
| 2014 Q2 | 46.47 Million CNY | 0.0% |
| 2014 Q4 | 57.44 Million CNY | -7.44% |
| 2014 Q3 | 62.05 Million CNY | 33.54% |
| 2014 Q1 | - CNY | -100.0% |
| 2014 FY | 57.44 Million CNY | 28.88% |
| 2013 Q4 | 44.57 Million CNY | 0.0% |
| 2013 FY | 44.57 Million CNY | -4.78% |
| 2012 FY | 46.81 Million CNY | 66.97% |
| 2011 FY | 28.03 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 8.02 Billion CNY | 81.877% |
| Hangzhou Tigermed Consulting Co., Ltd. | 5.22 Billion CNY | 72.192% |
| Dirui Industrial Co.,Ltd. | 1.26 Billion CNY | -15.174% |
| Medicalsystem Biotechnology Co., Ltd. | 772.59 Million CNY | -88.223% |
| Maccura Biotechnology Co.Ltd | 1.5 Billion CNY | 3.554% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.15 Billion CNY | -25.677% |
| Guangdong Hybribio Biotech Co.,Ltd. | 615.23 Million CNY | -136.365% |
| BGI Genomics Co., Ltd. | 3.6 Billion CNY | 59.706% |
| Amoy Diagnostics Co., Ltd. | 221.04 Million CNY | -557.878% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1 Billion CNY | -44.453% |